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sthma and COPD are common conditions that 
account for substantial morbidity and mortality 
worldwide. Asthma affects 5% to 10% of adults, of 
whom 10% have severe disease.    1,2     Severe asthma rep-
resents a disproportionate health-care burden as it 
leads to debilitating chronic symptoms despite opti-
mal standard asthma treatment and contributes to 
more than half of the health-care costs attributed to 
asthma.  1-4     COPD is predicted to be the third leading 
cause of death in 2030.    5,6     Both conditions are charac-
terized by airﬂ  ow obstruction with airway inﬂ  amma-
tion and remodeling. 
  COPD is considered a neutrophilic airway dis-
ease with increased inﬁ  ltration of the airway with 
CD8  1    T cells,    7     whereas asthma is characterized by 
Th2 cytokine expression and eosinophilic inﬂ  amma-
tion.  8     However, there is increasing recognition that 
asthma and COPD are diseases with phenotypic 
heterogeneity in terms of clinical expression, airway 
dysfunction, and immunopathology.    9,10    Indeed,  the 
    Background:       Asthma and COPD are characterized by airway dysfunction and inﬂ  ammation. Neu-
trophilic airway inﬂ  ammation is a common feature of COPD and is recognized in asthma, particu-
larly in severe disease. The T helper (Th) 17 cytokines IL-17A and IL-17F have been implicated 
in the development of neutrophilic airway inﬂ  ammation, but their expression in asthma and 
COPD is uncertain. 
    Methods:       We assessed IL-17A and IL-17F expression in the bronchial submucosa from 30 subjects 
with asthma, 10 ex-smokers with mild to moderate COPD, and 27 nonsmoking and 14 smoking 
control subjects. Sputum IL-17 concentration was measured in 165 subjects with asthma and 
27 with COPD. 
    Results:       The median (interquartile range) IL-17A cells/mm  2   submucosa was increased in mild to 
moderate asthma (2.1 [2.4]) compared with healthy control subjects (0.4 [2.8]) but not in severe 
asthma (  P    5    .04). In COPD, IL-17A    1     cells/mm  2   submucosa were increased (0.5 [3.7]) compared 
with nonsmoking control subjects (0 [0]) but not compared with smoking control subjects ( P    5   .046). 
IL-17F    1     cells/mm  2   submucosa were increased in severe asthma (2.7 [3.6]) and mild to moderate 
asthma (1.6 [1.0]) compared with healthy controls subjects (0.7 [1.4]) (  P    5    .001) but was not 
increased in subjects with COPD. IL-17A and IL-17F were not associated with increased neutro-
philic inﬂ  ammation, but IL-17F was correlated with the submucosal eosinophil count (  r  s  5   0.5, 
  P    5    .005). The sputum IL-17 concentration in COPD was increased compared with asthma 
(2 [0-7] pg/mL vs 0 [0-2] pg/mL,   P    ,    .0001) and was correlated with post-bronchodilator FEV  1  % 
predicted (  r    5    2  0.5,   P    5   .008) and FEV  1  /FVC (  r    5    2  0.4,   P    5   .04). 
    Conclusions:       Our ﬁ  ndings support a potential role for the Th17 cytokines IL-17A and IL-17F in 
asthma and COPD, but do not demonstrate a relationship with neutrophilic inﬂ  ammation. 
  CHEST 2010; 138(5):1140–1147 
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  Expression of the T Helper 17-Associated 
Cytokines IL-17A and IL-17F in Asthma 
and COPD 
  Camille    Doe,    MSc;      Mona    Bafadhel,    MBChB;    Salman    Siddiqui,    PhD; 
  Dhananjay    Desai,    MBBS;    Vijay    Mistry,    BSc;      Paul    Rugman,    PhD;   
  Margaret    McCormick,    BSc;    Joanne    Woods ,   PhD ;   Richard    May,    PhD;   
  Matthew  A.    Sleeman,    PhD;    Ian  K.    Anderson,    PhD;  and    Christopher  E.    Brightling,    PhD,  FCCP  www.chestpubs.org CHEST / 138 / 5 / NOVEMBER, 2010    1141 
sured the IL-17A sputum concentration and the num-
ber of IL-17A and F    1    cells in the bronchial mucosa 
and assessed the degree of neutrophilic inﬂ  ammation 
in the airway in asthma and COPD. 
  Materials and Methods 
 Subjects 
  Subjects were recruited from hospital staff and general respira-
tory and “Difﬁ  cult Asthma” clinics at Glenﬁ  eld Hospital, Leicester; 
local primary health care; and by local advertising. Asthma was 
deﬁ  ned according to the current Global Initiative for Asthma 
(GINA) guidelines.    2     Subjects with asthma had typical symptoms 
and the presence of one or more of the following objective crite-
ria: signiﬁ  cant bronchodilator reversibility of FEV  1   .   200 mL, a 
provocation concentration of methacholine causing a 20% fall in 
FEV  1   (PC 20  ) of   ,   8 mg/mL, or a peak ﬂ  ow amplitude percent 
mean over 2 weeks of   .   20%. Asthma severity was classiﬁ  ed using 
the GINA treatment steps (mild to moderate 1-3, severe 4-5).    2   
COPD was diagnosed and severity categorized by using Global 
Initiative for Chronic Obstructive Lung Disease criteria.    6    Sub-
jects with COPD who demonstrated partial bronchodilator 
reversibility were not excluded. Subjects were recruited as three 
independent cross-sectional groups, to assess IL-17 A, F, and IL-17R 
expression in proximal airways in asthma (group 1) and COPD 
(group 2), and sputum IL-17 concentration in asthma and COPD 
(group 3). Subjects were free from exacerbations for at least 
6 weeks. Healthy control subjects had normal spirometry and some 
smokers with   .   10 pack-year history were included to enable com-
parisons between healthy smokers and subjects with COPD. Sixty-
eight of 295 subjects had participated in an earlier report.    20    All 
subjects gave written informed consent with study approval from 
the Leicestershire ethics committee. 
 Protocol 
  Demographics and spirometry were recorded for all subjects. 
Subjects with asthma and healthy control subjects in group 1 
and 2 also underwent methacholine inhalation test using 
the tidal breathing method    21     and allergen skin prick tests for 
  Dermatophagoides pteronyssinus  , dog, cat, and grass pollen. Spu-
tum induction was performed in all subjects in groups 1 and 2.    22   
  In group 1, subjects underwent bronchoscopy conducted 
according to the British Thoracic Society guidelines,    23    and 
biopsies were taken from the right middle and lower lobe cari-
nae. In group 2, proximal airway samples were collected from 
surgical specimens. All bronchial mucosal specimens were ﬁ  xed 
in acetone and embedded in glycomethacrylate as described 
previously.  24   
  Sputum IL-17 Measurement 
  Sputum was selected, dispersed using the mucolytic dithio-
threitol (DTT), and processed to generate a sputum differential 
cell count, and cell-free supernatants were stored at -80°C for 
later analysis as described previously.    25     Sputum IL-17 was mea-
sured by enzyme-linked immunosorbent assay (ELISA) (R&D 
Systems Europe Ltd; Abingdon, England). The lower limit of 
detection was 15 pg/mL. The IL-17 assay was validated in line 
with European Respiratory Society recommendations to assess 
the effect of DTT and the recovery of exogenous spiking with 
recombinant cytokine.    25     IL-17 recovery was not affected by DTT 
and mean recovery of exogenous spiked IL-17 was 93% (n   5  16). 
application of induced sputum to study large groups 
of patients with airway disease has suggested that 
there is considerable overlap between these condi-
tions, with neutrophilic inﬂ  ammation observed in up 
to 40% of patients with asthma, particularly in those 
with severe disease.    11     Therefore, there is a pressing 
need to further understand the potential mechanisms 
involved in the initiation and persistence of neutro-
philic inﬂ  ammation in airways disease. 
  A distinct T-cell lineage, called T-helper (Th)17 cells, 
has been identiﬁ  ed and characterized by the pro-
duction of IL-17A, IL-17F, and IL-22.    12    In  addition 
to  CD4   1      cells, IL-17A and F can be released by 
neutrophils, eosinophils, CD8    1    T cells, basophils, 
and mast cells.    13     Both cytokines can induce the 
expression of a variety of proinﬂ  ammatory cytokines 
and chemokines in epithelial and vascular endothelial 
cells, ﬁ  broblasts, neutrophils, and eosinophils, includ-
ing IL-6, granulocyte macrophage colony-stimulating 
factor, CXCL10, and CXCL8.    14     The induction of 
CXCL8, a potent neutrophil chemokine, has impli-
cated these Th17 cytokines in the development of 
neutrophilic airway inﬂ  ammation.    13,14     In support of 
this view recent evidence from animal models dem-
onstrates that allergic sensitization through the airway 
primes strong Th17 responses that promote airway 
neutrophilia and airway hyperresponsiveness,    15    whereas 
IL-17F-deﬁ  cient mice have an impaired neutrophilic 
response to allergen.    16     In humans there is emerging 
evidence to support an increase in IL-17A and IL-17F 
expression in moderate to severe asthma    17,18    and 
COPD.  19     However, whether this expression is associ-
ated with granulocytic inﬂ  ammation in the airway wall 
or lumen is uncertain. 
  We hypothesized that IL-17A and IL-17F expres-
sion is increased in asthma and COPD and is related 
to disease severity and the intensity of neutrophilic 
inﬂ  ammation. To test our hypothesis we have mea-
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not compared with smoking control subjects, (  P   5   .046, 
Kruskal-Wallis;   P   ,    .05 COPD vs nonsmoking control 
subjects) (  Fig 2D  ). There were no differences in the 
number of IL-17F   1   cells/mm 2  submucosa in lung resec-
tion tissue from subjects with COPD and control 
subjects with and without a signiﬁ  cant smoking his-
tory (  Fig 2E  ,   Table 2  ). 
  The number of IL-17A    1    cells was correlated with 
FEV  1  % predicted (  R s  5   0.38;  P   5   .04), and the sputum 
neutrophil count (  R s  5    2 0.43,   P   5    .03) in asthma but 
was not associated with the number of neutrophils or 
eosinophils in the bronchial mucosa (  Table 3    ). The 
number of IL-17F    1    was positively correlated with the 
number of eosinophils in tissue (  rs   5   0.50;   P   5   .005) 
but not signiﬁ  cantly correlated with lung function or 
neutrophil number in tissue or sputum (  Table 3  ). 
  Sputum IL-17 Asthma and COPD 
  Sputum IL-17 was below the limit of detection in 
all samples from subjects with asthma (n   5   22), sub-
jects with COPD (n   5   22), and control subjects (n   5   12) 
measured by ELISA. Using the mesoscale device 
IL-17 was also measured in a further independent population 
of subjects with COPD and asthma using the mesoscale device 
platform.  26   
  IL-17A and IL-17F Expression in Endobronchial Biopsies 
  Two-micrometer sections were cut and stained using poly-
clonal antibodies against IL-17A and IL-17F (R&D Systems 
Europe Ltd), monoclonal antibodies against eosinophils (major 
basic protein), neutrophils (neutrophil elastase), and mast cells 
(tryptase), with appropriate isotype controls mouse IgG1 (Dako 
UK Ltd; Cambridge, England) and goat immunoglobulins (R&D 
Systems Europe Ltd). The number of positive nucleated cells 
was enumerated per mm  2   of bronchial submucosa by a blinded 
observer as described previously.    27,28     In a subgroup of six subjects 
with asthma, IL-17A and IL-17F were colocalized with neutrophils 
and eosinophils using sequential sections as previously described.    27   
 Statistical  Analysis 
  Statistical analysis was performed using PRISM Version 4 
(GraphPad; La Jolla, CA). Parametric data were expressed as mean 
(SEM), data that had a normal log distribution were log transformed 
and described as geometric mean (95% CI), and nonparametric 
data were described as median (interquartile range [IQR]). One-way 
analysis of variance (Kruskal-Wallis for nonparametric data) was 
used for across-group comparisons with Tukey and Dunn post hoc 
tests for between-group comparisons, respectively. Correlations 
were assessed by Spearman rank (  rs  ) and Pearson (  r  ) correlation 
coefﬁ  cients. No corrections were made for multiple comparisons. 
 Results 
  IL-17A, IL-17F, and IL-17R Expression 
in Large Airway Tissue Specimens 
  Clinical characteristics of group 1 are as shown 
in   Table 1    . Examples of IL-17A    1    and IL-17F    1    cells in 
the bronchial submucosa in asthma are as shown in 
  Figures 1A-1C    . The median (IQR) IL-17A cells/mm  2  
submucosa was increased in mild to moderate asthma 
(2.1 [2.4]) compared with healthy control subjects 
(0.4 [2.8]) but not compared with asthma (0.9 [4.2]) 
(  P   5    .04, Kruskal-Wallis;   P   ,    .05 mild to moderate 
asthma vs control subjects) (  Fig 1D  ). The number 
of IL-17F    1    cells/mm 2   submucosa was increased 
in severe asthma (2.7 [3.6]) and mild to moderate 
asthma (1.6 [1.0]) compared with healthy control 
subjects (0.7 [1.4]) ( P   5   .001 Kruskal-Wallis;  P   ,  .01 
severe asthma vs control subjects, and   P   ,   .05 mild to 
moderate vs control subjects) (  Fig 1E  ). The median 
(IQR) proportion 50% (27%) and 24% (19%) of the 
IL-17A  1    and 44% (40%) and 0 (25%) of IL-17F cells 
colocalized to neutrophils and eosinophils, respectively. 
  Clinical characteristics of group 2 are as shown in 
  Table 2    . All of the COPD subjects were ex-smokers. 
Examples of IL-17A    1    and IL-17F    1    cells in the 
bronchial submucosa in COPD are as shown in 
  Figures 2A-2C    . The median (IQR) IL-17A    1    cells/mm 2  
submucosa was increased in COPD (0.5 [3.7]) com-
pared with nonsmoking control subjects (0 [0]), but 
  Table 1—  Clinical and Sputum Characteristics of Biopsy 
Group Asthma   
Characteristic   Normal  
Mild to 
Moderate 
Asthma 
(GINA 1-3)
Severe Asthma 
(GINA 4-5)
No. 17 17 13
Age  a    45 (5) 49 (4) 50 (4)
Men/women 7/10 8/9 6/7
Never smokers/current 
  smokers/ex-smokers
15/2/0 12/5/0 8/5/0
Pack-years  a    0.4 (0.3) 3 (1) 5 (3)
Atopy, No. (%) 6 (35) 9 (53) 7 (54)
PC  20 FEV 1 ,  mg/mL  b     .  16 0.33 (0.14-0.78)    c   0.38  (0.1-1.4)  c  
FEV  1  , % predicted    a    99 (4) 87 (5) 80 (7)    c  
Pre-BD FEV  1 /FVC,  %  a    78 (3) 74 (3) 74(3)
BD response, %    a    1 (1) 9 (4)    c   13  (6)  c  
Sputum cell counts
 TCC    a    1.9 (0.4) 2.7 (0.7) 2.7 (0.6)
 Eosinophil,  %    d    0.3 (0.9) 0.5 (3.2) 6.6 (14.6)    c  
 Neutrophil,  %    a    43 (12) 54 (6) 59 (10)
 Macrophage,  %    a    51 (9) 38 (6) 25 (6)    c  
 Lymphocyte,  %    a    1.8 (0.8) 1.0 (0.2) 1.5 (0.7)
  Epithelial cells, %    a    3 (2) 4 (1) 7 (3)
Cells/mm  2   submucosa
 IL-17A    d    0.4 (2.8) 2.1 (2.4)    c   0.9  (4.2)
 IL-17F    d    0.7 (1.4) 1.6 (1.0)    c   2.7  (3.6)  c  
 Mast  cells    d    24.4 (23) 28.8 (31.8) 25.8 (56.5)
 Neutrophils    d    8 (13) 9.3 (12.7) 8.2 (11.5)
 Eosinophils    d    3.0 (9) 6.2 (18.9) 10.0 (41.2)
BD  5   bronchodilator;  GINA  5    Global Initiative for Asthma; IQR    5   inter-
quartile range; PC  20   5   provocation concentration causing a 20% fall in 
FEV  1 ;  SE  5   standard error  ; TCC   5   total cell count  .
  a Mean  (SE).
  b  Geometric mean (95% CI).
  c  P   ,   .05 compared with control subjects.
  d Median  (IQR).www.chestpubs.org CHEST / 138 / 5 / NOVEMBER, 2010    1143 
post-bronchodilator FEV  1  % predicted (  r   5    2 0.5, 
  P   5   .008) and FEV  1 /FVC ( r   5    2 0.4,  P   5   .04) ( Figs 3A-3C ). 
The clinical characteristics of these subjects with 
asthma and COPD are as shown (  Table 4    ). 
 Discussion 
  We report here that IL-17A expression in the bron-
chial submucosa was increased in mild to moderate 
platform the sputum IL-17 concentration in COPD 
was increased compared with asthma (2 [0-7] pg/mL 
vs 0 [0-2] pg/mL,   P   ,   .0001) and was correlated with 
  Figure   1. IL-17A and IL-17F expression in the submucosa in 
asthma. Representative photomicrographs of bronchial biopsy 
sections from subjects with severe asthma, illustrating isotype 
control. A, Goat IgG. B, IL-17A    1    cells present in the bronchial 
submucosa. C, IL-17F    1    cells in the submucosa (  3   400). IL-17A/F    1   
cells highlighted by arrows. D, The number of IL-17A    1    and 
E, IL-17F    1    cells in the bronchial submucosa of healthy control sub-
jects, subjects with mild to moderate asthma (Global Initiative for 
Asthma [GINA] 1-3), and subjects with severe asthma (GINA 4-5). 
  P   values for across-group comparison by Kruskal-Wallis test and 
Dunn post hoc test for between-group comparisons are as shown.       
  Table 2—  Clinical Characteristics and IL-17A and 
IL-17F Expression in COPD   
Characteristic Normal Smoker COPD
No. 10 14 10
Age  a    59 (3) 53 (5) 65 (3)
Men (women) 8 (2) 10 (4) 7 (3)
Never smokers/current 
  smokers/ex-smokers
8/0/2 0/0/14 0/0/10
Pack-years  a    2 (1) 28 (5) 37 (6)    b  
FEV  1   a    2.7 (0.2) 2.6 (0.2) 1.7 (0.2)    b  
FEV  1  , % predicted    a    86 (3) 84 (3) 62 (3)    b  
Pre-BD FEV  1 /FVC  a    78 (2) 78 (1) 56 (3)    b  
Cells/mm  2   submucosa
  IL-17A 0 (0) 0 (1.1) 0.5 (3.7)    b  
  IL-17F 0 (1.7) 0 (0) 0.2 (2)
See Table 1 legend for expansion of the abbreviation.
  a Mean  (SE).
  b  P   ,   .05 compared with nonsmoking control subjects.
  Figure   2. IL-17A and IL-17F expression in the submucosa in 
COPD. Representative photomicrographs of proximal airway 
resections from COPD tissue, illustrating isotype control. A, Goat 
IgG. B, IL-17A    1    cells present in the submucosa. C, IL-17F    1    cells 
in the submucosa (  3   400). IL-17A/F    1    cells highlighted by arrows. 
D, The number of IL-17A    1    and E, IL-17F    1    cells in the submucosa 
of healthy control subjects (never smokers), healthy control sub-
jects (smokers), and subjects with COPD.   P   values for across-
group comparison by Kruskal-Wallis test and Dunn post hoc test 
for between-group comparisons are as shown.      
  Table 3—  Correlations Between IL-17A/F, Granulocytic 
Inﬂ  ammation, and Lung Function in Asthma   
Characteristic IL-17A IL-17F
Neutrophils/mm  2   submucosa   r s  5    2 0.05,   P   5   .8  r s  5   0.32,  P   5   .078
Sputum neutrophils (%)   r s  5    2 0.43,   P   5   .03  r s  5    2 0.15,   P   5   .45
Eosinophils/mm  2   submucosa   r s  5   0.2,  P   5   .3  r s  5   0.50,  P   5   .005
Sputum eosinophils, %   r s  5   0.09,  P   5   .7  r s  5   0.08,  P   5   .7
FEV  1  , % predicted   r s  5   0.38,  P   5   .04  r s  5    2 0.06,   P   5   .8
FEV  1 /FVC,  %   r s  5   0.35,  P   5   .06  r s  5    2 0.17,   P   5   .39
Methacholine PC  20 FEV 1    r s  5    2 0.17,   P   5   .5  r s  5    2 0.25,   P   5   .25
 rs   5   Spearman rank correlation coefﬁ  cient. See Table 1 legend for 
expansion of the other abbreviation.1144  Original Research
submucosa. However, there was a good correlation 
between the number of IL-17F    1    cells and eosino-
phils in the bronchial submucosa. In COPD there 
was a highly signiﬁ  cant, albeit small, increase in spu-
tum IL-17 compared with asthma, and this was cor-
related with airflow obstruction and lung function 
impairment, but not airway inﬂ  ammation. Our study 
therefore supports our hypothesis that IL-17 may 
play a role in asthma and COPD. 
  There is an increasing body of evidence supporting 
a role for Th17 cells in asthma.    13,14     Animal models of 
asthma suggest that Th17 cytokines promote neutro-
philic inﬂ  ammation,    15,16     which in concert with Th2 cells 
is important in the development of airway hyperre-
sponsiveness.  17     Previous reports have demonstrated 
increased IL-17A and IL-17F bronchial submucosa 
expression in moderate to severe asthma,    17,18    which 
were attenuated by systemic corticosteroids.    17    The 
data for sputum IL-17 is conﬂ  icting with one study 
demonstrating no differences in the sputum IL-17 con-
centration between asthma and healthy volunteers,    29   
whereas in another study IL-17 was increased in 
moderate to severe asthma.    30     In the latter study spu-
tum IL-17 was measured before and after inhaled 
corticosteroids. Importantly, consistent with our ﬁ  nd-
ings previous studies have found that the sputum 
IL-17 concentration in sputum is low and in some 
studies samples have needed to be concentrated to 
detect IL-17. We found that IL-17A and IL-F were 
increased in mild to moderate disease, whereas IL-17F 
but not IL-17A was increased in severe asthma. Our 
subjects with severe asthma were treated with high-
dose inhaled and/or oral corticosteroids, and there-
fore this may have attenuated the IL-17A expression 
in this group. IL-17A and IL-17F expression was not 
associated with smoking status but importantly this 
study was not powered to fully explore the effects of 
asthma, and IL-17F was increased in mild to moderate 
and severe asthma. In contrast, in ex-smoking subjects 
with mild to moderate COPD the number of IL-17A   1   
cells in the bronchial submucosa, but not IL-17F, 
was increased compared with nonsmoking control 
subjects. In asthma there was a weak relationship 
between the number of IL-17A   1   cells and the FEV  1 % 
predicted, and the sputum neutrophil count. There 
was no association between neutrophilic inﬂ  amma-
tion and IL-17A or F expression in the bronchial 
  Figure   3. Sputum IL-17 in asthma and COPD. A, Sputum IL-17 
concentration in asthma and COPD. Horizontal bar represents the 
median. B, Correlations between sputum IL-17 concentration in 
subjects with COPD and postbronchodilator FEV  1 %  predicted. 
C, Correlations between sputum IL-17 concentration in subjects 
with COPD and FEV  1 /FVC.   
  Table 4—  Clinical Characteristics and IL-17A and 
IL-17F Sputum Concentration in Asthma and COPD   
Characteristic COPD (n   5   27) Asthma (n  5   165)
Age  a    68 (1.6) 50 (1.1)
Men, % 74 41
Never smokers/current 
 smokers/ex-smokers
0/18/9 109/44/12
Pack years    a    47 (6) 15 (3)
Post-BD FEV  1 ,  L  a    1.1 (0.1) 2.2 (0.1)
Post-BD FEV  1  , % predicted    a    42 (3) 76 (2)
Post-BD FEV  1 /FVC  %  a    44 (2) 70 (1)
Sputum neutrophil count, %    a    65 (5) 63 (2)
Sputum eosinophil count, %    b    1.5 (0.9-2.7) 2.7 (2.1-3.5)
Sputum IL-17, pg/mL    c    2 (0-7) 0 (0-2)
See Table 1 legend for expansion of the abbreviation.
  a Mean  (SE).
  b  Geometric mean (95% CI).
  c Median  (IQR).www.chestpubs.org CHEST / 138 / 5 / NOVEMBER, 2010    1145 
IL-17 concentration in COPD was related to the 
degree of airﬂ  ow limitation and obstruction. Therefore, 
the potential role of IL-17, particularly in severe dis-
ease, and its synergy with the development of airway 
inﬂ  ammation in response to cigarette smoke exposure 
or alternatively through interactions with other cyto-
kines, such as tumor necrosis factor    35    or  IL-1 b ,  36    needs 
to be further explored. 
  Neutrophils were the predominant source of 
IL-17 as evidenced by colocalization using immuno-
histochemistry. However, there was no correlation 
between the number of IL-17    1    cells and neutrophils 
in the bronchial submucosa. In contrast to the estab-
lished role of IL-17A and IL-17F in the initiation of 
neutrophilic inﬂ  ammation, neither has been impli-
cated in the development of eosinophilic inﬂ  am-
mation. Indeed, IL-17F transgenic mice develop an 
airway neutrophilia after allergen challenge, whereas 
knockout mice have an impaired neutrophilic response 
and enhanced Th2 cytokine production.    16    Therefore, 
we were surprised by the relationship between the 
number of IL-17F    1    cells and eosinophils in the bron-
chial submucosal. However, a similar relationship has 
been described between sputum IL-17 mRNA and 
IL-5 mRNA,    33     possibly suggesting a hitherto unde-
scribed association between eosinophilic airway inﬂ  am-
mation and the Th17 axis. Eosinophils express the 
IL-17 receptors and have enhanced cytokine release 
after IL-17F activation.    37     Thus, the potential interactions 
between eosinophilic inﬂ  ammation and up-regulation 
of the Th17 axis require further study. 
  Our study has a number of possible criticisms. This 
is a cross-sectional observational study. Whether 
IL-17A and IL-17F expression is related to longitudi-
nal clinical outcomes, such as disease progression, 
lung function decline, and exacerbations, requires fur-
ther examination. Similarly, we are unable to deter-
mine whether differences observed between mild and 
severe asthma reﬂ  ect disease severity or are a conse-
quence of differences in treatment. Current litera-
ture suggests that IL-17A is sensitive to corticosteroid 
therapy,  17,30     in contrast to neutrophilic inﬂ  ammation, 
which is corticosteroid resistant.    31,32    Importantly,  the 
number of IL-17A or IL-17F cells was expressed as 
cells/mm  2   of submucosa rather than as a proportion 
of the total number of cells in the submucosa. There-
fore, whether the changes in cell number between 
groups is a reﬂ  ection of increased expression or an 
increase in the total number of cells needs to be 
examined in future studies. We are conﬁ  dent that our 
assays to assess IL-17 were robust as recovery was 
unaffected by the mucolytic DTT and recovery of 
exogenous spikes of IL-17 to sputum samples was 
good. However, a number of samples were below 
the limit of detection; therefore, the sputum data do 
need to be interpreted cautiously. Furthermore, no 
smoking in asthma. We report for the ﬁ  rst time, to 
our knowledge, the relationship between IL-17A and 
F expression and neutrophilic inﬂ  ammation in tissue 
and sputum. We found that there was no associa-
tion between IL-17A and IL-17F expression neutro-
philic inﬂ  ammation in tissue. Intriguingly, there was a 
weak inverse correlation between submucosal IL-17A 
expression and the sputum neutrophil count. Corti-
costeroids attenuate IL-17 expression in tissue    17    but 
do not modulate sputum neutrophil counts.    31,32    Spu-
tum IL-17 was also markedly attenuated by inhaled 
corticosteroids, but the sputum neutrophil count was 
unchanged, questioning the role of IL-17 in per-
sistent neutrophilic airway inﬂ  ammation. However, 
others have demonstrated an association between 
IL-17 and IL-8 mRNA in sputum cells and the num-
ber of sputum neutrophils,    33     suggesting that the site 
of IL-17 expression may be important. Interestingly, 
we also found a weak relationship between FEV  1 % 
predicted and IL-17A expression. Consistent with 
our ﬁ  nding in a recent comparison between subjects 
with severe asthma with and without persistent air-
ﬂ  ow obstruction, IL-17 was among the dominant 
mediators associated with the absence of persistent 
airﬂ  ow obstruction.    34     Together these ﬁ  ndings do not 
support a role for IL-17 in the development of ﬁ  xed 
airﬂ  ow obstruction in asthma. 
  To date there are few data examining the expression 
of IL-17A or IL-17F in COPD. Neutrophilic inﬂ  am-
mation is a common feature of COPD.    7,11     Hence, it is 
predictable that IL-17 may play an important role in 
this disease. There is a single report of IL-17A and F 
expression in bronchoscopic biopsies obtained across 
the spectrum of COPD disease severity compared 
with smoking and nonsmoking control subjects.    15    IL-17A 
was increased equally across the severity of COPD 
compared with the nonsmoking control subjects, but 
was not different from the smoking control subjects. 
IL-17F was not signiﬁ  cantly different across all the 
disease and control groups. In this study the number 
of neutrophils in tissue was increased in the COPD 
groups with a marked increase in severe COPD. There 
was no relationship between IL-17A and IL-F expres-
sion and neutrophilic inﬂ  ammation. Our ﬁ  ndings 
of increased IL-17A expression in mild to moderate 
COPD compared with nonsmoking control subjects, 
but not smoking control subjects, is therefore entirely 
consistent with these earlier reports. We found that 
the sputum IL-17 concentration was increased in COPD 
compared with asthma. However, we were unable to 
detect IL-17 by ELISA, and with a more sensitive 
mesoscale device platform a substantial proportion 
still remained below the limit of detection. The differ-
ence between COPD and asthma was highly signiﬁ  -
cant, but small, questioning whether this difference 
is biologically important. Interestingly, the sputum 1146  Original Research
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corrections for multiple comparisons were made. 
Therefore, ﬁ  ndings with a marginal level of signiﬁ  -
cance also need to be interpreted with caution. 
  In conclusion, we found that IL-17A expression 
in bronchial submucosa was increased in mild to 
moderate asthma and in COPD, although this was not 
independent of smoking. IL-17F expression was 
increased in mild to moderate and severe asthma, 
but not in COPD. The increased IL-17A and IL-17F 
expression was not associated with increased neutro-
philic inﬂ  ammation. Sputum IL-17 was increased in 
COPD and was related to airﬂ  ow obstruction. Our 
ﬁ  ndings therefore do support a potential role for 
IL-17A and IL-17F in asthma and possibly COPD. 
Efﬁ  cacy studies of therapeutic strategies targeted at 
the IL-17 axis are eagerly awaited that will further 
deﬁ  ne the functional importance of IL-17A and IL-17F 
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